Navigation Links
John Theurer Cancer Center researchers shed light on new multiple myeloma therapy
Date:7/25/2012

anced multiple myeloma, however, it has been shown to cause peripheral neuropathy in approximately 38 percent of treated patients with subcutaneous administration.

Phase II 004 Clinical Trial Results for Advanced Myeloma

Dr. Siegel and Dr. Vesole served as co-investigators on an 18-center, phase II open-label efficacy and safety clinical trial, also known as 004, of carfilzomib in combination with Bortezomib, another proteasome inhibitor. The study was published in the June 14th issue of Blood.

"We saw significant responses in patients considered more difficult to treat, including those with more advanced disease and poor prognoses," said Dr. Siegel, the senior author of the study. "Our results support the potential use of carfilzomib in this patient population."

The researchers enrolled 129 patients with multiple myeloma who had relapsed following one to three previous courses of treatment. Patients treated with bortezomib were excluded, as it is in the same drug class as carfilzomib and its use might make the effect of carfilzomib more difficult to determine. The study's primary endpoint was overall response rate. Researchers also measured patients' responses at various intervals as well as time to disease progression, and recorded reactions (adverse events) to treatment.

The most common adverse events in the study were fatigue (62 percent) and nausea (48.8 percent), while 17.1 percent of patients developed peripheral neuropathy, mostly Grades 1 and 2. Peripheral neuropathy, damage to nerves that fan out across the body from the brain and spinal cord, causes pain and other symptoms; lower grades have less severe symptoms. Peripheral neuropathy has been reported in 37-70 percent of myeloma patients receiving other commonly used drug therapies.

"Our myeloma team is leading the way in innovative research that makes promising therapies available to our patients, while also continually testing new
'/>"/>

Contact: Amy Leahing
aleahing@p4strategy.com
305-458-0599
John Theurer Cancer Center
Source:Eurekalert

Page: 1 2 3 4 5

Related medicine news :

1. Experts from John Theurer Cancer Center to participate in the AAMDSIF Patient and Family Conference
2. John Theurer Cancer Center hosting 8th Annual Neuro-Oncology Symposium
3. New probe provides vital assist in brain cancer surgery
4. Researchers find driver of breast cancer stem cell metastasis
5. Novel pig model may be useful for human cancer studies
6. Colonoscopy screening markedly reduces colorectal cancer incidence and death
7. A new route for tackling treatment-resistant prostate cancer
8. Antioxidants Might Help Cut Pancreatic Cancer Risk, Study Suggests
9. Young Cancer Patients Often Lack Support: Study
10. Media alert: 24th EORTC - NCI - AACR Symposium Molecular Targets and Cancer Therapeutics
11. Tel Aviv University research links childhood obesity to cancer risk
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/12/2014)... The "North American ... Market by Angioplasty Balloon (Plain/Old, Cutting), ... IVC Filter (Retrievable), Endovascular Stent Graft ... studies the major market drivers, restraints, ... Canada. , Browse 108 market data ...
(Date:7/12/2014)... (PRWEB) July 12, 2014 Tylenol ... continue to move forward in the federal multidistrict ... of Pennsylvania, Bernstein Liebhard LLP reports. According to ... Judge Lawrence F. Stengel has ordered the deposition ... Judge Stengel found that the witness’s testimony concerning ...
(Date:7/12/2014)... ON Canada (PRWEB) July 12, 2014 Sean Francis, ... for throwing out special challenges to his clients. He’s also known ... Club. He recently found a way to combine the two and ... has raised $2,000 for the Boys and Girls Club. , The ... Program, which started on June 23rd. Francis sent out emails and ...
(Date:7/12/2014)... CA (PRWEB) July 12, 2014 For those ... are bodies can readily absorb the nutrients in food. The ... particles that are small enough to be absorbed by human ... team, a lack of enzymes in regular food is the ... a product that was started by Michelle DelPresto, a mother ...
(Date:7/12/2014)... Utah (PRWEB) July 12, 2014 Utah ... types of startups, with awards being bestowed to companies ... spotlighted Utah’s outstanding entrepreneur community with recognition for new ... sustainable model with incoming revenue. , 25 Under 5 ... the state that are under 5 years old. Award ...
Breaking Medicine News(10 mins):Health News:North American Interventional Cardiology & Peripheral Vascular Devices Market - New Report by MarketsandMarkets 2Health News:North American Interventional Cardiology & Peripheral Vascular Devices Market - New Report by MarketsandMarkets 3Health News:North American Interventional Cardiology & Peripheral Vascular Devices Market - New Report by MarketsandMarkets 4Health News:North American Interventional Cardiology & Peripheral Vascular Devices Market - New Report by MarketsandMarkets 5Health News:Tylenol Lawsuit News: U.S. District Judge Overseeing Federal Tylenol Liver Damage Litigation Orders Deposition of Former McNeil President, Bernstein Liebhard LLP Reports 2Health News:Tylenol Lawsuit News: U.S. District Judge Overseeing Federal Tylenol Liver Damage Litigation Orders Deposition of Former McNeil President, Bernstein Liebhard LLP Reports 3Health News:Tylenol Lawsuit News: U.S. District Judge Overseeing Federal Tylenol Liver Damage Litigation Orders Deposition of Former McNeil President, Bernstein Liebhard LLP Reports 4Health News:Kawartha Lakes Fit Body Boot Camp’s Successful Fat Loss Challenge Results in $2,000 to Boys and Girls Club 2Health News:Kawartha Lakes Fit Body Boot Camp’s Successful Fat Loss Challenge Results in $2,000 to Boys and Girls Club 3Health News:New Super Digestive Enzyme, DZ10, Supercharges The Digestion Process 2Health News:SquareHook is Recognized for UVEF 25 Businesses Under 5 Years-Watch Out 2
... A nontoxic nanoparticle developed by Penn State researchers is ... both therapeutic drugs and the fluorescent dyes that can ... of Nano Letters , an interdisciplinary group of ... calcium phosphate particles ranging in size from 20 to ...
... late adulthood, the number of patients with Alzheimer,s disease (AD) ... , A team of national researchers, led by Emory ... cognitive impairment (MCI) often the earliest stage of AD. ... Journal of Alzheimer,s Disease . , The study shows ...
... Author/Therapist Provides New Resource So Families of ,Bad, Children Can ... ORMOND BEACH, Fla., Nov. 18 The holidays ... the stress of the season can foster difficult, even disorderly ... outbursts can destroy a family gathering and leave parents asking, ...
... 18 Women who have decided that they do ... sterilization. Patients who opt for hysteroscopic sterilization need to ... and return to daily activities, also consists of 2 ... (HSG). Both parts of the procedure must be performed ...
... a drug rehab program does not mean they have ... recovery and return to addiction and abuse soon after. ... the patient?" Usually it,s their family and ... counterattack these situations by offering family weekends four times ...
... innovative, cost-effective medical devices, announces immediate availability of an economical ... designed to bring affordable cytology to any size laboratory. ... ... EON) November 18, 2008 -- The NuView System does ...
Cached Medicine News:Health News:Nontoxic nanoparticle can deliver and track drugs 2Health News:Nontoxic nanoparticle can deliver and track drugs 3Health News:New approach to screen individuals for early Alzheimer's disease 2Health News:New Site DrNorm.com Offers Hope and Healing to Parents of 'Difficult' Children During Holiday Season & Beyond 2Health News:New Site DrNorm.com Offers Hope and Healing to Parents of 'Difficult' Children During Holiday Season & Beyond 3Health News:C.A.R.E. Florida Launches Family Weekends to Help on That Long Road to Recovery 2Health News:C.A.R.E. Florida Launches Family Weekends to Help on That Long Road to Recovery 3
(Date:7/11/2014)... -- Rock Creek Pharmaceuticals, Inc. (NASDAQ: RCPI ), ... and Drug Administration ("FDA"), has notified the Company that ... Drug ("IND") application before granting the Company permission to ... Dr. Chris Chapman , RCP,s President, commented, "We ... When we receive the agency,s official comments and/or recommendations, ...
(Date:7/11/2014)... 11, 2014  Australian drug delivery company, Phosphagenics Limited ... raised A$19.3 million via a placement of A$16.3 million ... the U.S., Asia and ... share purchase plan (SPP) to be offered to existing ... in two tranches. "This capital raising positions ...
(Date:7/11/2014)... , July 11, 2014 ... visitors to Safety & Health Expo 2014 ... the move to London ... management attending exhibition.     ... http://photos.prnewswire.com/prnh/20140711/696892-a )      ...
Breaking Medicine Technology:Rock Creek Pharmaceuticals Issues Update On US Investigational New Drug Application 2Phosphagenics' A$19.3 million Capital Raising 2Phosphagenics' A$19.3 million Capital Raising 3UK's Flagship Health & Safety Event Has Successful Inaugural Year in London 2UK's Flagship Health & Safety Event Has Successful Inaugural Year in London 3UK's Flagship Health & Safety Event Has Successful Inaugural Year in London 4
... Surgical Company (Nasdaq: STAA ), the leading ... today announced that the Visian Implantable Collamer® Lens (ICL) ... leading ophthalmologists at meetings prior to and during the ... Surgeons (ESCRS) held in Paris, France from September 4 ...
... Present at the Rodman & Renshaw Annual Global... -- SHENZHEN, China, Sept. 8 /PRNewswire-Asia/ -- ... ... --> ... var s = ,; var first_result; // Results are keyed by longUrl, so we need to grab ...
Cached Medicine Technology:STAAR Surgical Launches New Visian ICL™ Product Line Extensions at ESCRS 2STAAR Surgical Launches New Visian ICL™ Product Line Extensions at ESCRS 3STAAR Surgical Launches New Visian ICL™ Product Line Extensions at ESCRS 4STAAR Surgical Launches New Visian ICL™ Product Line Extensions at ESCRS 5STAAR Surgical Launches New Visian ICL™ Product Line Extensions at ESCRS 6Winner Medical Group Inc. to Present at the Rodman & Renshaw Annual Global Investment Conference on September 13 at 3:40 pm ET 2Winner Medical Group Inc. to Present at the Rodman & Renshaw Annual Global Investment Conference on September 13 at 3:40 pm ET 3Winner Medical Group Inc. to Present at the Rodman & Renshaw Annual Global Investment Conference on September 13 at 3:40 pm ET 4Winner Medical Group Inc. to Present at the Rodman & Renshaw Annual Global Investment Conference on September 13 at 3:40 pm ET 5Winner Medical Group Inc. to Present at the Rodman & Renshaw Annual Global Investment Conference on September 13 at 3:40 pm ET 6Winner Medical Group Inc. to Present at the Rodman & Renshaw Annual Global Investment Conference on September 13 at 3:40 pm ET 7
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: